Combining the targeted precision of monoclonal antibodies with the potent destructive power of cytotoxic payloads, Antibody-Drug Conjugates (ADCs) represent a…
Read More
Novo Nordisk Secures FDA Approval for Awiqli, a Once-Weekly Basal Insulin for Adults with Type 2 Diabetes
The United States Food and Drug Administration (FDA) has granted approval to Novo Nordisk for Awiqli (insulin icodec-abae) injection 700…
Read More
Simulations Plus Forges Strategic Alliances to Pioneer AI-Driven Drug Development
Simulations Plus, a leading provider of advanced modeling and simulation software for drug discovery and development, has announced the establishment…
Read More
Novartis to Acquire Excellergy for Up to $2 Billion to Bolster Next-Generation Anti-IgE Allergy Pipeline
Novartis has entered into a definitive agreement to acquire Excellergy, a privately held biotechnology company specializing in the development of…
Read More
Darzalex Secures Landmark European Approval for Self-Administration in Multiple Myeloma, Ushering in a New Era of Home-Based Cancer Care
Johnson & Johnson’s (J&J) groundbreaking cancer immunotherapy, Darzalex (daratumumab), has achieved a pivotal milestone in its European market penetration with…
Read More
Europe’s Biopharmaceutical Competitiveness and Commercial Strategies Under Scrutiny at BIO Europe Spring
Lisbon, Portugal – As the vibrant city of Lisbon recently concluded its tenure as host for the annual BIO Europe…
Read More
Recordati Weighs CVC’s €10.9 Billion Acquisition Offer, Potentially Delisting from Italian Stock Exchange
Italian pharmaceutical giant Recordati is currently in deliberations regarding a significant acquisition offer from global private equity firm CVC Capital…
Read More
Rocket Pharmaceuticals Secures Landmark FDA Approval for Kresladi, Ushering in a New Era for Ultra-Rare Immune Disease Treatment
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rocket Pharmaceuticals’ Kresladi (marnetegragene autotemcel), a groundbreaking gene…
Read More
Corcept’s first-in-class ovarian cancer drug gains FDA approval – Pharmaceutical Technology
Corcept Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its selective…
Read More
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
In a significant move poised to accelerate the innovation pipeline for antibody-drug conjugate (ADC) therapies, Japanese pharmaceutical giant Daiichi Sankyo…
Read More
